Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06160752 · ClinicalTrials.gov registry record · Phase 1
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
A Phase 1 study of Solid Tumor and Intrahepatic Cholangiocarcinoma, sponsored by Tyra Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 4
- Study locations
NCT06160752: Recruiting Phase 1 study of Solid Tumor and Intrahepatic Cholangiocarcinoma, sponsored by Tyra Biosciences.
NCT06160752 is a Phase 1 study of Solid Tumor and Intrahepatic Cholangiocarcinoma that is actively recruiting participants, run by Tyra Biosciences. The registered enrollment target is 40 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (82% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06160752, a Phase 1 study of Solid Tumor and Intrahepatic Cholangiocarcinoma, is actively recruiting participants, sponsored by Tyra Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-200 in cancers with FGFR2 activating gene alterations, including unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma and other advanced solid tumors.
Conditions Studied
Interventions
- DRUG Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles
- DRUG Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles
Study Locations (4)
California
- University of California San Francisco (UCSF) - San Francisco
Massachusetts
- Massachusetts General Hospital - Boston
Ohio
- The Ohio State University - Columbus
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-11-22 |
| Est. Completion | 2027-09 |
| Phase | Phase 1 |
What NCT06160752 shows while recruiting
NCT06160752 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (82% lower).
The record links to 4 conditions, with Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles is the first listed.
NCT06160752 reports a single indexed study location in California, Massachusetts, Ohio.
Frequently Asked Questions
What is clinical trial NCT06160752 about?
NCT06160752 is a clinical study titled "Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-200 in cancers with FGFR2 activating gene alterations, including unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma and other advanced solid tumo...
What is the current status of trial NCT06160752?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2023-11-22. Estimated completion is 2027-09.
What conditions does trial NCT06160752 study?
This clinical trial studies the following conditions: Solid Tumor, Intrahepatic Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Locally Advanced Cholangiocarcinoma.
What interventions are being tested in trial NCT06160752?
The interventions under investigation include: Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles (DRUG), Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles (DRUG).
Who is sponsoring clinical trial NCT06160752?
This trial is sponsored by Tyra Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06160752 being conducted?
This trial has 4 study locations across California, Massachusetts, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06160752's enrollment target sits among peer trials
40 141st of 196 higher than 54 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI